Semaglutide: Artificial Shortage Is Novo Nordisk’s Business Model

In early February, drug company Novo Nordisk sued telehealth company Hims & Hers. The complaint: Hims & Hers sells GLP-1 drugs at lower prices than Novo Nordisk. That’s the simple version. The legalese version is that because semaglutide (the drug behind the Novo Nordisk’s “Wegovy” brand name) was removed from the US Food and Drug … Continue reading Semaglutide: Artificial Shortage Is Novo Nordisk’s Business Model → - by Thomas L. Knapp


https://thegarrisoncenter.org/archives/20370?utm_source=dlvr.it&utm_medium=blogger